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Copyright © 2009 JCBN Summary Hemorrhagic shock causes oxidative stress that leads to tissue injuries in various
organs including the lung, liver, kidney and intestine. Excess amounts of free heme released
from destabilized hemoproteins under oxidative conditions might constitute a major threat
because it can catalyze the formation of reactive oxygen species. Cells counteract this by rap-
idly inducing the rate-limiting enzyme in heme breakdown, heme oxygenase-1 (HO-1), which
is a low-molecular-weight stress protein. The enzymatic HO-1 reaction removes heme. As such,
endogenous HO-1 induction by hemorrhagic shock protects tissues from further degeneration
by oxidant stimuli. In addition, prior pharmacological induction of HO-1 ameliorates oxida-
tive tissue injuries induced by hemorrhagic shock. In contrast, the deletion of HO-1 expres-
sion, or the chemical inhibition of increased HO activity ablated the beneficial effect of HO-1
induction, and exacerbates tissue damage. Thus, HO-1 constitutes an essential cytoprotective
component in hemorrhagic shock-induced oxidative tissue injures. This article reviews recent
advances in understanding of the essential role of HO-1 in experimental models of
hemorrhagic shock-induced oxidative tissue injuries with emphasis on the role of its induction
in tissue defense.
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Introduction
Hemorrhagic shock (HS) triggers a systemic inflammatory
response that culminates in multiple organ failure with
significantly high mortality and morbidity [1]. Exaggerated
systemic inflammatory responses comprise an important
component of HS-induced tissue injury [2]. Both hypoxia-
reoxygenation and neutrophil activation enhance this
systemic inflammatory response [2] by generating reactive
oxygen species (ROS), which ultimately leads to tissue
injury [3].
Heme is a prosthetic group in hemoproteins, such as
hemoglobin, myoglobin, cytochrome c, cytochrome P450,
catalase and peroxidase, all of which are critically important
for cellular vitality [4, 5]. In contrast, “free heme”, which is
not bound to a protein and can be released from destabilized
hemoprotein by oxidative stimuli such as HS, is quite toxic,
since it catalyzes ROS production [5]. The body is equipped
with various protective mechanisms to defend against
excessive free heme concentrations. Heme oxygenase (HO)
is a key factor in the defense mechanism, and it plays a
fundamental role against oxidative processes mediated by
free-heme, including HS [6].
Heme Oxygenase-1 is the rate-limiting enzyme in heme
catabolism. It oxidatively cleaves heme to yield one molecule
each of iron, carbon monoxide (CO), and biliverdin IXα
(biliverdin), the last of which is subsequently reduced by
biliverdin reductase to bilirubin IXα (bilirubin) (Fig. 1) [7].
At least two isozymes for HO have been identified; HO-1 is
induced in response to various stimuli [7], whereas HO-2 is
constitutively expressed and not inducible [8]. The expres-
sion of HO-1 is upregulated in various cell types not only by
its substrate heme but also by a vast array of stressful stimuli
including oxidative stress [6].
The two enzymatic products of the HO reaction, i.e.,
biliverdin and CO can be toxic at very high concentrations.
However, recent evidence indicates that they are not toxic at
physiological concentrations in normal cells, and that they
may also have important anti-oxidant, anti-inflammatory, or
anti-apoptotic properties [9, 10]. Thus, in addition to the
removal of free heme, i.e., a potent pro-oxidant, HO-1
induction results in the production of anti-oxidant molecules
that function the protective response and contribute to the
suppression of oxidative tissue injuries [6,  11–13]. The
importance of HO-1 in protection against oxidative stresses
is further substantiated by previous studies that show a
reduction in the protective responses against oxidant stress
of  ho-1 knockout mutant mice and in a patient with an
inherited HO-1 deficiency [14, 15]. In the case of the patient,
the absence of HO-1 was associated with abnormally elevated
serum heme concentrations (~500 μM), and various inten-T. Takahashi et al.
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sive oxidative as well as massive inflammatory complica-
tions [15]. The powerful adaptive response to oxidative
stress suggests an entirely new role for HO-1 in protection
against inflammatory processes induced by HS and suggests
that HO-1 is an essential component in the biological defen-
sive response against HS-induced oxidative tissue injuries.
Injury after HS is unique in that a global insult is delivered
to all organ systems, such as the liver, kidney, intestine and
lung, indicating that HS is a systemic injury. The role of
HO-1 in single organ ischemia/reperfusion (I/R) injury
including transplant-related injury has already been exten-
sively reviewed [16–19]. Thus, the present review empha-
sizes the protective role of HO-1 in a model of HS-induced
oxidative tissue injury in vivo.
Induction of HO-1 and Its Protective Role in
Hemorrhagic Shock-Induced Oxidative Tissue Injury
Ischemia-induced oxidative tissue injury can frequently
cause destabilization of hemoproteins which results in an
increase in intracellular free heme concentration. Both hemin,
an oxidized form of heme that is available as a chemical, and
tissue inflammation obviously induce HO-1 [6,  11–13],
suggesting a possible role of HO-1 in the protection of
HS-induced oxidative stress. Recent evidence indicates that
HO-1 induction is essential to maintain the physiological
milieu against oxidant stimuli in animal models of HS.
1. Hemorrhagic shock-induced hepatic injury and HO-1
HS elicits the formation of significant amount of ROS in
the liver not only by hepatic hypoxia-reoxygenation itself,
but also by immune activation due to gut bacterial transloca-
tion [2], which leads to oxidative hepatic injury. Thus, HS
induces HO-1 in the liver, and this process plays a
significant protective role against HS-induced hepatic injury.
1-1. Induction of hepatic HO-1 by hemorrhagic shock-
induced ROS generation. HS leads to a substantial increase
in hepatic HO-1 mRNA and protein primarily in paren-
chymal cells at the midzonal and pericentral region in rats
[20]. The potent antioxidant “Trolox” significantly attenuates
the HS-induced increase of HO-1 in hepatocytes [21]. More-
over, Kupffer cell blockade by the treatment of gadolium
chloride and antioxidants abolished HO-1 mRNA and
protein induction after HS [22]. These results suggest that
oxygen-free radicals released by Kupffer cells serve as
paracrine regulator of HO-1 gene expression. We also found
that HO-1 mRNA and protein levels obviously increased in
hepatocyte after HS (Fig. 2A) [23], whereas mRNA levels of
non-specific 5-aminolevulinate synthase (ALAS1), which is
down-regulated by heme [24], significantly decreased after
HS (Fig. 2B). Cytochrome P450, a major hemoprotein in the
liver, undergoes a rapid degradation upon ischemia [25],
which results in the release of pro-oxidant free heme.
Collectively, these findings suggest that increased levels of
free heme in hepatocytes also contribute to the induction of
HO-1 after HS mediated through the enhanced production of
oxygen free radicals.
1-2. Protective role of HO-1 in hemorrhagic shock-induced
hepatic injury. The role of hepatic HO-1 induction after HS
has been evaluated in animals with HS administered with
tin-protoporphyrin (SnPP), a specific competitive inhibitor
of HO activity [26] at 5 h after the onset of resuscitation
[20]. Increases in the incidence of pericentral necrosis and in
the level of serum α-glutathione-S-transferase, a sensitive
marker of hepatocyte injury indicates aggravated hepatic
injury [20]. These findings suggest that HO-1 induced by HS
protects hepatocytes from HS-induced, tissue injury.
1-2-1. Dobutamine ameliorates hemorrhagic shock-induced
hepatic dysfunction through induction of HO-1. Recent
evidence suggests that increased intracellular cyclic AMP
levels induce HO-1 via protein kinase A-dependent pathway
[27]. Intracellular cyclic AMP levels are increased in the
Fig. 1. Oxidative catabolism of heme. HO catalyzes the oxidative
conversion of heme, to biliverdin IXα, releasing carbon
monoxide (CO) and ferrous iron as reaction products.
Biliverdin IXα is subsequently reduced to bilirubin IXα
by biliverdin reductase.Protective Role of HO-1 in Hemorrhagic Shock
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liver by several receptor-dependent pathways including
adrenoceptor agonists. The β1-receptor agonist dobutamine
induces HO-1 mRNA and protein via protein kinase A
pathway in hepatocytes in vitro and in vivo [28]. Whereas
HS significantly impairs liver function judged as a decrease
in the disappearance rate of indocyanine green in rat plasma,
prior dobutamine administration induces significant amounts
of HO-1 in hepatocytes around the central vein and
improves hepatic dysfunction after HS [29]. This protective
effect was abrogated by blocking the HO pathway with
tin-mesoporphyrin (SnMP), a specific competitive inhibitor
of HO activity [30]. A blockade of β1-adorenoceptors with
esmolol also attenuates the induction of HO-1 and the dis-
appearance rate of indocyanine green from plasma [29].
These results suggest that the β1-adrenocepter-dependent
up-regulation of HO-1 induced by dobutamine contributes to
improved hepatic function after HS.
2. Hemorrhagic shock-induced renal injury and HO-1
The kidney is vulnerable to oxidative damage caused by
ischemia, ultimately progressing to acute renal failure [31].
Thus, ROS and HO-1 have both been implicated in
HS/ischemia-induced renal injury.
2-1. Heme-mediated HO-1 induction in the kidney after
hemorrhagic shock. HS resulted in increased renal HO-1
mRNA and protein expression in tubular epithelial cells
(Fig. 2B) [23] whereas the level of ALAS1 mRNA in the
kidney rapidly fell (Fig. 2B). Ischemia of the rat kidney
decreases the amount of microsomal cytochrome P450 [32].
Cytochrome P450 represents the major source of heme in
the kidney because of its high content and rapid turnover
[33]. Collectively, the increase in the concentration of free
heme presumably released from microsomal cytochrome
P450 may contribute to HO-1 induction after HS. Levels of
microsomal heme and HO-1 mRNA concomitantly increase
in the rat kidney after 30 min of bilateral renal ischemia [32],
suggesting that HO-1 induction is also mediated by heme in
this model.
2-2. HO-1 induction is necessary in restoring ischemic renal
injury. The significance of HO-1 induction after HS has
been examined using the rat model of renal ischemia. Renal
ischemia for 40 min in uni-nephrectomized rats significantly
induces HO-1 mRNA and its enzyme activity after kidney
reperfusion [34]. The inhibition of HO activity by SnMP
results in a rapid, obvious increase in the intracellular heme
content, and in the aggravation of renal function [34]. Thus,
HO-1 induction in this model also plays a critical role in
protecting the kidney against oxidative damage induced by
ischemia.
2-2-1. HO-1 deficiency exacerbates ischemic renal injury
and augments systemic inflammation induced by renal
ischemia. The protective role of HO-1 in acute renal injury
Fig. 2. Effect of hemorrhagic shock on gene expression of heme oxygenase-1 (HO-1) and non-specific 5-aminolevulinate synthase
(ALAS1) in the liver and kidney. Rats were subjected to HS for 60 min followed by resuscitation. After the onset of resuscita-
tion, time course changes in HO-1 (closed circle) and ALAS1 (open circle) mRNA expression were examined by Northern blot
analysis. HO-1 mRNA was rapidly and markedly increased in the liver (A) and kidney (B) after HS, while ALAS1 mRNA
levels were drastically decreased immediately after HS, suggesting that there may be an abnormal increase in “free heme”
concentrations in the liver and kidney after HS.T. Takahashi et al.
J. Clin. Biochem. Nutr.
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caused by ischemia has been further examined in HO-1
knockout mice. Renal function in HO-1 knockout mice
shows obvious deterioration after relatively mild renal
ischemia, reflected by increased blood urea nitrogen and
serum creatinine levels [35]. Renal ischemia also causes
increased mortality in HO-1 knockout mice, unlike the wild
type mice. The surviving HO-1 knockout mice show distinct
histological renal injury, which is accompanied by increased
activation of NF-κB and NF-κB-dependent proinflam-
matory genes such as monocyte chemoattractant protein-1
[35]. Moreover, IL-6 mRNA is clearly induced not only in
the kidney, but also in the lung and heart of HO-1 deficient
mice after renal ischemia. Systemic levels of IL-6 after
ischemia are also increased in HO-1 knockout mice
compared with wild-type mice [36]. The administration of
an antibody to IL-6 protects against the renal dysfunction
and mortality observed in HO-1 knockout mice after ischemia
[36], suggesting that augmented systemic inflammation
following renal ischemia in an HO-1-deficient state is
responsible for the exaggerated vulnerability observed in
this setting.
2-3. Amelioration of ischemic renal injury by HO-1 induc-
tion specific to renal epithelial cells. Although tin is an
essential trace element for some animals, whether it is
essential for humans remains unknown. Growth is retarded
in rats with tin deficiency syndrome [37], whereas excessive
concentrations of tin cause various side effects in humans
such as gastrointestinal complaints [38]. Uniquely, treating
rats with tin potently and exclusively induces HO-1 in the
kidney [39]. Moreover, tin chloride (SnCl2) administration
before renal ischemia significantly improves renal dysfunc-
tion, since increased serum creatinine levels are suppressed
[40]. Proximal tubular cells are significantly damaged in
control animals pretreated with vehicle, while minimally
damaged with SnCl2 [40]. Elevated levels of renal HO-1
mRNA after SnCl2 administration are followed by increases
in HO-1 protein expression and HO activity, and HO-1
protein specifically accumulates in renal tubular epithelial
cells [40]. Tin chloride significantly attenuates the sustained
increase in the microsomal heme concentration caused by
ischemia [40]. In contrast, the inhibition of HO activity
induced by SnMP results in microsomal heme accumulation,
and abolishes the beneficial effect of SnCl2 on ischemic
renal injury, indicating that HO-1 plays a fundamental role
in protecting renal epithelial cells from oxidative damage
due to ischemic insult by removing the pro-oxidant “free
heme” [40].
2-4. Attenuation of ischemic renal injury by HO-1 induced in
infiltrating macrophages by statins. Statins are a class of
lipid lowering drugs that inhibit the enzyme, 3-hydroxy-3
methylglutaryl-coenzyme A reductase, and they have recently
emerged as potentially powerful inhibitors of the inflam-
matory process [41]. The mechanism through which statins
modulate the immune response is complex, but it is often
regarded as being independent of cholesterol lowering
activity [ 41]. Recent findings indicate that the anti-
inflammatory effects of statins are linked to HO-1 induction
[42, 43]. Administering rats with statins reduces subsequent
renal damage and attenuates renal dysfunction after renal
ischemia [44]. The protective effect of statins is abolished
by the co-administration of SnPP [44]. Renal ischemia
increases HO-1 expression both at the transcript and protein
level in the kidney. This effect is significantly more evident
in animals pretreated with statin. Moreover, infiltrating
macrophages comprise the major source of tissue HO-1
production [44]. Collectively, in addition to HO-1 induction
in renal epithelial cells, local HO-1 delivery from infiltrating
macrophages induced by statins may exert anti-inflammatory
effects, thereby reducing oxidative tissue injuries caused by
renal ischemia.
3. Hemorrhagic shock-induced intestinal tissue injury and
HO-1
The intestine plays a critical role in the pathogenesis of
HS-induced multiple organ damage as a site of end-organ
injury and as an activator of the immune response via
bacterial translocation [45]. ROS greatly contribute to HS-
induced gut injury [3]. Therefore, HO-1 induced in the
mucosal epithelial cells of the intestine after HS confers
protection against oxidative intestinal tissue injury caused
by HS [46].
3-1. Site-specific induction of HO-1 in hemorrhagic shock-
induced intestinal tissue injury. Following HS, significant
amounts of HO-1 are induced in the mucosal epithelial cells
of the rat duodenum, jejunum and colon, but not at all in the
ileum [46]. In contrast, intestinal tissue injury and inflam-
mation are more pronounced in the ileum than in other
regions of the intestine [46]. These findings suggest that the
intestinal sites where HO-1 can be induced after HS are
better protected from oxidative tissue injury than sites where
HO-1 cannot be induced. In addition, the prior administra-
tion of SnMP to animals results in mucosal epithelial cell
injury and inflammation in the duodenum, jejunum and
colon but not of the ileum according to the augmented gene
expression of proinflammatory mediators, such as tumor
necrosis factor (TNF)-α and inducible nitric oxide synthase
(iNOS) [46]. Injury and inflammation are further indicated
by increased apoptotic DNA fragmentation as evidenced by
increased number of positive cells in the oligo ligation assay
in situ; increased protein expression of activated caspase-3
to carry out the apoptotic process; and decreased gene
expression of Bcl-2 for an anti-apoptosis [46]. Thus, HO-1
induction and the maintenance of its activity are critical in
the protection of the intestinal epithelial cells from oxidative
injury induced by HS.Protective Role of HO-1 in Hemorrhagic Shock
Vol. 44, No. 1, 2009
33
3-1-1. Concordant expression of HO-1 and hypoxia inducible
factor-1α in the intestine after hemorrhagic shock. Hypoxia
inducible factor (HIF)-1α is a hypoxia responsive helix-
turn-helix transcription factor with a binding sequence in the
ho-1 promoter [47]. Since HIF-1α coordinates hypoxia-in-
duced HO-1 expression [47], it is probably involved in the
site-specific HO-1 expression in the intestine induced by
HS. Thus, we examined the effect of HS on expression of
HIF-1α in various regions of the intestine. Levels of HIF-1α
mRNA rapidly increased in the duodenum, jejunum and
colon at the ischemic phase of HS. In contrast, levels in the
ileum were not influenced by HS (Fig. 3A). Consistent with
enhanced HIF-1α gene expression, HIF-1α protein staining
was positive and increased in the duodenum, jejunum and
colon after HS, but not in the ileum (Fig. 3B). Positive HIF-
1α protein principally stained the mucosal cells of the intes-
tine where HO-1 protein was also expressed. This site-spe-
cific induction and the cellular localization of HIF-1α pro-
tein are consistent with those of HO-1 induction after HS,
suggesting that HIF-1α contributes to the site-specific induc-
tion of intestinal HO-1 after HS.
3-2. Protection of the hemorrhagic shock-induced intestinal
tissue injury by glutamine by its HO-1 induction.
Glutamine is now recognized as an essential nutrient
during serious injury and illness [48]. Glutamine helps to
prevent infectious morbidity and mortality in seriously ill
patients [48] by maintaining the integrity of the intestinal
mucosal epithelium [49]. Levels of HO-1 mRNA and
protein are up-regulated in the mucosal epithelial cells of the
ileum of rats treated with glutamine [50, 51]. Furthermore,
HS-induced intestinal tissue injury in the ileum is also
significantly suppressed by glutamine compared with
untreated controls. Thus, glutamine significantly ameliorates
HS-induced mucosal injury, inflammation and apoptotic cell
death by inducing HO-1 [51]. In contrast, SnMP abolishes
the beneficial effect of glutamine, indicating that the protec-
tive effect of glutamine in HS-treated animals is principally
mediated by its ability to induce HO-1 [51].
4. Hemorrhagic shock-induced lung injury and HO-1
HS causes neutrophil sequestration in the lung, which
leads to acute lung injury (ALI) and its more severe form,
acute respiratory distress syndrome, both of which are
responsible for the significant morbidity and mortality of
critically ill patients [52,  53]. Reactive oxygen species
generated from infiltrating neutrophils play pivotal roles in
the pathogenesis of ALI [3]. However, a specific therapy for
oxidative stress is not available [54]. Several studies have
indicated that pharmacologically induced pulmonary HO-1
overexpression protects lung cells from HS-induced oxida-
tive injury.
4-1. Amelioration of hemorrhagic shock-induced acute lung
injury by HO-1 induction. HS significantly increases pul-
monary HO-1 mRNA expression in rats. Prior hemoglobin
administration further increases HO-1 expression and
significantly ameliorates HS-induced pulmonary edema in
Fig. 3. Site-Specific induction of hypoxia inducible factor
(HIF)-1α in the intestine by hemorrhagic shock (HS).
Rats were subjected to hemorrhagic shock for 60 min
followed by resuscitation. Intestines were excised after
the onset of HS and dissected into the duodenum,
jejunum, ileum and colon. (A) Time course changes in
HIF-1α mRNA expression were examined in each
region of the intestine by Northern blot analysis. (B)
HIF-1α protein expression was examined by immuno-
histochemical analysis 30 min after the onset of HS and
the number of HIF-1α positive cells was counted. Sham,
sham-operated control animals; HS; HS animals. Data
are presented as mean ± SEM (n = 6). *p<0.01 vs. HS-
treated ileum. †p<0.01 vs. regional matched Sham. Both
HIF-1α mRNA levels and the number of HIF-1α posi-
tive cells were markedly increased in the ileum but not in
other regions of the intestine at the early phase of HS.T. Takahashi et al.
J. Clin. Biochem. Nutr.
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this model [55]. In contrast, SnPP abolishes the protection
induced by hemoglobin [55]. These findings suggest that the
pharmacological induction of HO-1 is beneficial in treating
HS-induced ALI, whereas the inhibition of HO activity by
SnPP abrogates the beneficial effect of prior hemoglobin
administration.
Heme arginate (HA) is a water-soluble and stable
metabolite of the reaction between hemin and L-arginine
[56] that is used to treat acute relapses in patients with acute
hepatic porphyria [57]. We found that administering HA to
rats induces functional HO-1 protein in pulmonary epithelial
cells, and significantly ameliorates subsequent lung injury
and inflammation induced by HS [23]. Prior HA administra-
tion decreases the expression of proinflammatory genes such
as TNF-α and iNOS, the DNA binding activity of NF-κB,
pulmonary edema and the neutrophil content in the lungs,
whereas subsequent HO-1 inhibition by SnMP mitigates
these beneficial effects of HA [23,  58]. Thus, similar to
prior administration with hemoglobin, that of HA confers
significant tissue protection in this model, suggesting that
this type of HO-1 induction significantly inhibits lung
damage induced by HS.
Critical Role of Free Heme in Hemorrhagic Shock-
Induced Oxidative Tissue Injury
Heme is an essential prosthetic group for hemoproteins,
which are vital for life [4, 5]. However, excess free heme is
a potentially cytotoxic iron-chelate through its ability to
catalyze membrane lipid peroxidation and form ROS [5, 59].
Ischemia of the kidney causes a decrease in the amount of
microsomal cytochrome P450, the major hemoprotein in the
rat kidney, with a concomitant increase in microsomal heme
content, followed by a significant induction of HO-1 mRNA
and protein [32]. Moreover, the inhibition of HO activity by
SnMP results in an obvious increase in microsomal heme
content and in the aggravation of renal dysfunction and
injury induced by renal ischemia [34]. Thus, an enhanced
and sustained increase in the intracellular free heme
concentration, which is presumably derived from hemo-
protein degraded by ischemic insult, exacerbates HS-
induced oxidative tissue injury; and rapid HO-1 induction
plays a key role in protecting cells from further damage due
to heme-mediated oxidative injury by removing pro-oxidant
free heme.
1. Free heme as an activator of inflammatory process
HS initiates an inflammatory response characterized by
up-regulated pro-inflammatory cytokine expression followed
by the migration of neutrophils into various tissues via the
activation of cell adhesion molecules [60]. Recent studies
indicate that free heme is involved in the activation of these
inflammatory cascades. Hemin induces neutrophil migration
in vivo and in vitro, triggers the oxidative burst, promotes
cytoskeleton reorganization and activates interleukin-8
expression in human neutrophils [61], suggesting that hemin
functions as a proinflammatory agent that induces neutrophil
activation. Moreover, exposing endothelial cells to hemin
stimulates the expression of adhesion molecules such as
ICAM-1, VCAM-1, and E-selectin, probably through the
heme-mediated generation of ROS [62,  63]. Heme also
induce TNF-α secretion by mouse peritoneal macrophages
dependently on MyD88, toll-like receptor (TLR) 4 and
CD14, although heme signaling through TLR4 depends on
an interaction distinct from that established between TLR4
and LPS [64]. Collectively, these findings suggest that free
heme is a potent activator of the innate immune response.
2. Role of Bach1 in ho-1 gene regulation and oxidative tissue
injury
Bach1 is a heme-responsive transcription factor that
represses ho-1 gene activation [65, 66]. Bach1 under base-
line conditions forms a heterodimer with small maf proteins
that represses transcription of the ho-1 gene by binding to
maf recognition elements (MARE) in the 5'-untranslated
region of the ho-1 promoter. Under conditions of excess
heme, increased heme binding to Bach1 causes a conforma-
tional change and a decrease in DNA-binding activity
followed by nuclear export of Bach1, which in turn leads to
transcriptional activation of the ho-1 gene through MARE
[65–67]. Heme also induced nuclear translocation of NF-E2-
related factor 2 (Nrf2), a partner molecule for the maf family
[68], and promotes stabilization of Nrf2 [69]. Thus, an
increased intracellular heme concentration displaces Bach1
from the MARE sequences by heme binding, which then
permits Nrf2 binding to a member of small maf proteins,
ultimately resulting in transcriptional activation of the ho-1
gene (Fig. 4) [66, 70, 71].
Bach1 may function as a sensor of oxidative stress [72].
Human Bach1 is a thiol-rich protein possessing 34 inter-
spersed cysteine amino acids, of which two are responsible
for Bach1 inactivation by oxidants [72]. Furthermore, HO-1
induction elicited by arsenite-mediated oxidative stress
follows inactivation of Bach1 and precedes Nrf2 activation
[72]. Bach1 repression is dominant over Nrf2-mediated
HO-1 transcription and Bach1 inactivation is prerequisite
for HO-1 induction [73]. Moreover, Bach1 specifically
represses induction of HO-1 elicited by arsenite [74]. These
findings collectively suggest that the redox regulation of
Bach1 serves as an alternative mechanism to HO-1 induc-
tion by oxidative stress (Fig. 4).
2-1. Bach1 inactivation leads to myocardial cytoprotection
involving HO-1 against ischemia/reperfusion injury.
Cardiac I/R injury induced after hemorrhagic shock is an
important example of oxidative tissue injuries [75]. Many
reports indicate that HO-1 plays a cytoprotective role againstProtective Role of HO-1 in Hemorrhagic Shock
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cardiac I/R injury [76–80]. Since Bach1 suppression leads
to HO-1 induction [71], Bach1 inactivation is apparently
decisive for deployment of the cytoprotective process
against oxidative stress, including ho-1 activation. The role
of Bach1 in tissue protection against myocardial I/R injury
has been investigated in vivo in mice lacking the Bach1 gene
[81]. The myocardial expression of HO-1 protein in Bach1-
deficient mice is constitutively up-regulated compared with
that in wild-type mice [81]. While myocardial I/R induces
HO-1 protein in ischemic myocytes from both strains of
mice, the extent of induction is significantly greater in the
Bach1-deficient, than in wild type mice [81]. Myocardial
infarction is clearly reduced in Bach1-deficient mice. Zinc-
protoporphyrin, an inhibitor of HO activity [82], abolishes
the infarction-reducing effect of Bach1 disruption in Bach1-
deficient mice [81], indicating that HO-1 activity mediates
Fig. 4. Protective role of heme oxygenase-1 (HO-1) in hemorrhagic shock-induced oxidative tissue injuries. Hemorrhagic shock (HS)
induces oxidative stresses which results in the production of free heme, presumably released from cytochrome P450 (CYP), or
from other hemoproteins. Free heme is then involved in the generation of reactive oxygen species (ROS) further to increase
oxidative stress. Binding of free heme with Bach1, the transcriptional repressor of ho-1, as well as the inactivation of Bach1 by
ROS allows the displacement of Bach1 from maf recognition element (MARE) sequence in the ho-1 promoter. This in turn
allows Nrf2 binding with MARE, and induces transcriptional activation of the ho-1 gene. Since HO-1 expression is known to be
principally regulated at the transcriptional level, this sequence of events leads to the increase in HO-1 protein and its enzymatic
activity. Increased HO-1 activity then metabolizes free heme to iron, CO and biliverdin. Iron is directly sequestered and
inactivated by co-induced ferritin. Biliverdin is rapidly converted to bilirubin by biliverdin reductase, and both bile pigments
serve as a major anti-oxidant. CO can suppress apoptosis of endothelial cells via the activation of p38 MAPK. In addition,
HO-1 is also induced by pharmacological treatment, such as glutamine and tin chloride, in a tissue-specific manner which is
targeted to the injured organs, and pre-induction of HO-1 by pharmacological means significantly ameliorates oxidative tissue
damages caused by HS. Thus, HO-1 is an essential cytoprotectective component against HS-induced oxidative tissue injuries
not only by removing excess amount of cytotoxic free heme but also by producing metabolites from heme which have anti-
oxidative and anti-apoptotic properties.T. Takahashi et al.
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the reduction in infarct size to some extent. Thus, Bach1
plays a pivotal role in establishing the levels of both
constitutive and inducible myocardial HO-1 expression.
Moreover, Bach1 inactivation during I/R appears to be a key
mechanism in controlling the activation of cytoprotective
processes involving HO-1.
Metabolites of HO Reaction Protect Against 
Hemorrhagic Shock-Induced Oxidative Tissue Injury
Heme oxygenase breaks down the pro-oxidant free heme
into iron, biliverdin and CO, thus resulting in a decrease in
oxidative stress. Iron, which is an oxidant, is directly
sequestered and inactivated by co-induced ferritin [83].
Heme Oxygenase-1 also prevents cell death by exporting
intracellular iron from cells both in vivo [84] and in vitro
[85]. Recent evidence suggests that the other two heme
metabolites, biliverdin and CO, also have significant anti-
oxidant properties. Thus, in addition to the removal of the
pro-oxidant free heme via oxidative metabolism, HO-1 in
turn produces a series of metabolites from heme, all of
which can act as important constituents of the host defense
system and contribute to the suppression of oxidative tissue
injuries.
1. Role of bile pigments in the protective response against
oxidative injury
Biliverdin is rapidly converted by bilirubin reductase to
bilirubin. Biliverdin and bilirubin, as well as their glucu-
ronides, are potent anti-oxidants (Fig. 4) [86]. The cellular
depletion of bilirubin by RNA interference directed against
biliverdin reductase increases tissue levels of ROS and
promotes apoptotic cell death, and the potent physiological
antioxidant actions of bilirubin reflect an amplification
cycle, in which bilirubin acting as an antioxidant is itself
oxidized to biliverdin and then recycled by biliverdin
reductase back to bilirubin [87]. Several epidemiological
studies indicate that mild to moderately elevated serum
bilirubin levels are associated with a better outcome in
diseases involving oxidative stress [88]. For instances, the
incidence of ischemic heart disease among middle-aged
individuals with Gilbert’s Syndrome, who have mild
unconjugated hyperbilirubinemia because of a genetic dis-
order of bilirubin conjugation, is reduced <5-fold compared
with the general population [89]. High plasma bilirubin
levels in the general population are also correlated with a
reduced risk of coronary heart disease [90–93].
1-1. Protective effects of biliverdin against endotoxin-
induced shock. Similar to HS, administering endotoxin to
animals incites a systemic inflammatory response that
mimics septic shock in clinical practice, ultimately leading
to multiple organ damage [94]. The effect of biliverdin on
endotoxin-induced shock has been investigated in rats ad-
ministered intravenously with lipopolysaccharide (LPS)
[95]. Administering rats with biliverdin before a lethal dose
of LPS significantly improves long-term survival, which is
associated with reduced serum levels of LPS-induced
proinflammatory IL-6 and augmented levels of anti-
inflammatory IL-10 [95]. Serum levels of bilirubin generated
after this dose of biliverdin are notably increased but remain
at high normal levels [95]. Biliverdin also ameliorates
LPS-induced lung permeability and lung aloveolitis, at least
in part, by blocking NF-κB activation [95]. Moreover,
biliverdin administered just after LPS also abrogates lung
inflammation [95]. The effects of biliverdin on IL-6 produc-
tion in mouse macrophage cells in vitro as well as in mouse
lung epithelial cells treated with LPS are similar [95]. These
findings not only indicate that biliverdin can modulate the
LPS-induced inflammatory response and suppress patho-
physiological changes in the lung, but also suggest that
biliverdin also exerts anti-inflammatory effects on HS-
induced tissue inflammation.
2. Protective role of carbon monoxide against oxidative
tissue injury
Carbon monoxide exerts anti-inflammatory and anti-
apoptotic effects in vitro and in vivo (Fig. 4). These effects
are thought to be mediated, at least in part, by activation of
the p38 MAPK signaling pathway [96,  97]. Heat shock
protein 70 mediates the anti-inflammatory and anti-
apoptotic effects of CO with the involvement of P38β
MAPK and heat shock factor-1, providing a downstream
mechanism for the cytoprotective effect of CO [98].
Moreover, the anti-oxidative effect of CO involves the
inhibition of upstream TLR signaling pathways [99]. Very
recently, it has been reported that the anti-inflammatory and
anti-apoptotic effect of CO can be attributed to its ability to
cause a relatively low intensity oxidative burst from the
mitochondria by inhibiting the electron transport chain
[100, 101]. Mitochondrial ROS induced by CO elicit the
activation of HIF-1α [102] and and PPARγ [103] both of
which are involved in the cytoprotecitive responses.
2-1. Inhalation of carbon monoxide attenuates HS-induced
systemic inflammation and ameliorates end organ injuries.
Carbon monoxide exerts cytoprotective effects in HS-
induced systemic inflammation and end-organ damage in a
rodent model of HS [104]. The delivery of a low concentra-
tion of CO (250 ppm) at the onset of HS decreases levels of
HS-induced serum IL-6, but augments HS-induced IL-10
levels in shocked mice, indicating that CO decreases the
systemic inflammatory response caused by HS [104].
Carbon monoxide inhalation also ameliorates HS-induced
lung, liver, and intestinal tissue injury as judged by the
decrease in lung MPO activity, serum ALT levels and the
preservation of architecture in the intestinal mucosa, respec-
tively [104]. Moreover, initiation of CO inhalation afterProtective Role of HO-1 in Hemorrhagic Shock
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resuscitation protected the lung and the liver from HS-
induced tissue injury [104]. These results suggest that CO
holds promise as a therapeutic adjunct in the treatment of
HS-induced oxidative tissue injuries, although the mecha-
nism is not well defined and optimal dose regimens and
therapeutic timing need to be determined.
Conclusions
This review summarizes recent evidence in support of
HO-1 induction as a major protective response against
HS-induced oxidative tissue injury. Pharmacological pre-
induction of HO-1 confers significant protection upon cells,
tissues and organs against oxidative damage induced by HS.
In addition to the protective role of HO-1, both bile pigments
and CO, the heme metabolites of the HO reaction, play
pivotal protective roles in tissues. These findings suggest
that HO-1 constitutes an essential cytoprotective component
in HS-induced oxidative tissue injuries, and that appropriate
HO-1 induction offers therapeutic promise for treating HS-
induced organ damage. However, further studies are
warranted to elucidate interspecies, or inter-cell type
differences in ho-1 gene expression [105], in order to make
better predictions from preclinical to clinical studies.
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